NovaBridge Biosciences (NBP) Other Operating Expenses (2024 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Other Operating Expenses of $32000.0 for Q4 2025, up 420.0% year-over-year from $6153.8 in Q4 2024, and up 100.22% quarter-over-quarter from -$14.5 million in Q3 2025.
NovaBridge Biosciences (NBP) Other Operating Expenses (2024 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Other Operating Expenses for 2 consecutive years, with $32000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Operating Expenses rose 420.0% year-over-year to $32000.0; the TTM figure through Dec 2025 stood at -$14.5 million (down 144520.0% YoY), while the FY2025 annual figure was $16000.0, up 245.45% from the prior year.
- Other Operating Expenses advanced to $32000.0 in Q4 2025 per NBP's latest filing, from -$14.5 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $32000.0 in Q4 2025 and bottomed at -$14.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | NovaBridge Biosciences | 215.85 Mn | 215.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32,000.00 |
| Sep 30, 2025 | -14.49 Mn |
| Dec 31, 2024 | -10,000.00 |